BioNexus Gene Lab Corp Files Form 10-Q for Period Ending September 30
BioNexus Gene Lab Corp filed its Form 10-Q for the period ending September 30, disclosing financial performance and condition for the quarter.
BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.
46 articles
BioNexus Gene Lab Corp filed its Form 10-Q for the period ending September 30, disclosing financial performance and condition for the quarter.
BioNexus Gene Lab reported a 98.12% drop in Q3 revenue for its Chemrex unit, resulting in a $1.88 million net loss. Auditors have expressed substantial doubt about the company's ability to continue as
BioNexus Gene Lab Corp initiated a pilot of its BGLC 1Lab workflow at its Malaysian subsidiary to enhance traceability from clinic orders to reports using GeneMatrix software and AI integration.
BioNexus Gene Lab Corp launched its BGLC 1Lab workflow pilot at its Malaysian subsidiary, MRNA Scientific, integrating clinical data with AI features. The company plans to incorporate Ruanyun Edai Tec
BioNexus Gene Lab Corp unveiled a redesigned website detailing its RNA screening, chemical business, and healthcare investments to improve investor access and reporting clarity.
BioNexus Gene Lab Corp launched a new website unifying data on its RNA screening, industrial chemicals, and healthcare investments. CEO Sam Tan noted the site helps stakeholders understand the company
Fidelion Diagnostics and three other parties filed a Schedule 13G disclosing 13.4% beneficial ownership of BioNexus Gene Lab Corp, with Fidelion retaining sole voting power over the shares.
BioNexus Gene Lab Corp signed an exclusive AI licensing agreement with Ruanyun Edai Technology to develop healthcare applications for Malaysia's public sector, aiming to digitize records in 150 hospit
BioNexus Gene Lab Corp secured an exclusive license for its CogniAI platform to support Malaysia's RM1 billion public healthcare digitization program, targeting 150 hospitals and 2,000 clinics through
Ruanyun Edai Technology Inc. granted BioNexus Gene Lab Corp. an exclusive license for its Cogni AI healthcare platform in Malaysia, involving a reciprocal share exchange and 10% royalty on technology
Ruanyun Edai Technology (RYET) licensed its Cogni AI platform exclusively to BioNexus Gene Lab for Malaysia's healthcare sector. The agreement includes a 10% royalty on qualifying receipts and a recip
BioNexus Gene Lab Corp awarded its CEO 338,709 fully vested common shares valued at $1.55 per share under the 2025 Equity Incentive Plan.
BioNexus Gene Lab Corp director Low Jook Yuen received 16,129 fully vested shares valued at $1.55 per share under the 2025 Equity Incentive Plan, increasing his direct holdings to 17,390 shares.
BioNexus Gene Lab Corp (BGLC) has released an earnings forecast detailing projected future EPS and revenue growth. The report covers market capitalization, recent price movements, and peer company com
Fidelion Diagnostics filed a Form 3 disclosing direct ownership of 392,329 shares in BioNexus Gene Lab Corp, establishing a >5% stake without recent transaction activity.
BioNexus Gene Lab Corp filed a Form 3 statement revealing Fidelion Diagnostics Pte. Ltd holds over 5% of common shares. The filing identifies Fidelion as a greater-than-5% holder with 392,329 shares a
BioNexus Gene Lab Corp filed an initial Form 3 for CFO Chong Set Fui on June 17, 2025, disclosing beneficial ownership details to the U.S. Securities and Exchange Commission.
BioNexus Gene Lab Corp (BGLC) reports a financial score of 6.04 despite a 98.93% year-over-year revenue drop to 22.84K. Net profit fell 12.79%, while several key operational metrics remain undisclosed
BioNexus Gene Lab Corp (BGLC) received a risk assessment score of 2.70 among 384 biotech companies, highlighting high volatility with a beta of 2.20 and a 78% maximum drawdown.
BioNexus Gene Lab Corp announced progress commercializing its VitaGuard™ molecular residual disease platform in Southeast Asia after technical planning visits to Chinese facilities. The company aims t
BioNexus Gene Lab Corp plans to commercialize its VitaGuard MRD liquid-biopsy platform in Southeast Asia by 2026, with test costs projected under $300. The rollout follows successful paid use in China
BioNexus Gene Lab Corp (NASDAQ:BGLC) reported Malaysia as its primary revenue contributor, generating $5.83 million last year, a decline from $7.46 million the previous year.
BioNexus Gene Lab Corp trades at $1.45, focusing on precision diagnostics and specialty chemical solutions through its subsidiaries. The company sells chemical raw materials in Southeast Asia and offe
BioNexus Gene Lab Corp (BGLC) presents earnings forecasts for future EPS and revenue growth, updated on July 26, 2026. The report includes financial health indicators and TradingKey stock scores.
BioNexus Gene Lab Corp shares traded at $1.510 with a minor decline. The report details key financial metrics including EPS, revenue forecasts, and balance sheet data for the FY2025 earnings period.
BioNexus Gene Lab Corp reported its cash flow statement, revealing an operating cash flow of -1.82M for fiscal 2025 and capital expenditures of 36.97K in the latest quarter. The data highlights the co
TradingKey analyzes BioNexus Gene Lab Corp, citing strong fundamentals and fair valuation within the Biotechnology sector. Despite recent market weakness, the company maintains significant growth pote
BioNexus Gene Lab Corp reported its shareholder structure, listing major holders like Fidelion Diagnostics and ARC Group, alongside institutional holdings data through Q1 2026.
BioNexus Gene Lab Corp (BGLC) holds a valuation score of 8.43, ranking 138th in the Biotechnology & Medical Research sector. Its P/E ratio is currently -1.02, though P/B, P/S, and P/CF data remain und
BioNexus Gene Lab Corp, a biotechnology firm specializing in chemical solutions and diagnostics, reports stock trading sideways near $1.510 with healthy fundamentals despite short-term bearish indicat